Pear Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0065
- Today's High:
- $0.0089
- Open Price:
- $0.0089
- 52W Low:
- $0.003
- 52W High:
- $3.33
- Prev. Close:
- $0.0091
- Volume:
- 642620
Company Statistics
- Market Cap.:
- $4.17 million
- Book Value:
- 0.218
- Revenue TTM:
- $12.69 million
- Operating Margin TTM:
- -938.18%
- Gross Profit TTM:
- $5.30 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -50.93%
- Return on Equity TTM:
- -124.76%
Company Profile
Pear Therapeutics Inc had its IPO on 2021-03-31 under the ticker symbol PEAR.
The company operates in the Healthcare sector and Biotechnology & Medical Research industry. Pear Therapeutics Inc has a staff strength of 200 employees.
Stock update
Shares of Pear Therapeutics Inc opened at $0.01 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.01 - $0.01, and closed at $0.01.
This is a -15.38% slip from the previous day's closing price.
A total volume of 642,620 shares were traded at the close of the day’s session.
In the last one week, shares of Pear Therapeutics Inc have slipped by -30%.
Pear Therapeutics Inc's Key Ratios
Pear Therapeutics Inc has a market cap of $4.17 million, indicating a price to book ratio of 4.7008 and a price to sales ratio of 21.695.
In the last 12-months Pear Therapeutics Inc’s revenue was $12.69 million with a gross profit of $5.30 million and an EBITDA of $-115125000. The EBITDA ratio measures Pear Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Pear Therapeutics Inc’s operating margin was -938.18% while its return on assets stood at -50.93% with a return of equity of -124.76%.
In Q4, Pear Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 94.3%.
Pear Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.36 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pear Therapeutics Inc’s profitability.
Pear Therapeutics Inc stock is trading at a EV to sales ratio of 17.4723 and a EV to EBITDA ratio of -1.6196. Its price to sales ratio in the trailing 12-months stood at 21.695.
Pear Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $95.13 million
- Total Liabilities
- $49.44 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $1.07 million
- Dividend Payout Ratio
- 0%
Pear Therapeutics Inc ended 2024 with $95.13 million in total assets and $0 in total liabilities. Its intangible assets were valued at $95.13 million while shareholder equity stood at $30.59 million.
Pear Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $49.44 million in other current liabilities, 14000.00 in common stock, $-323474000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $48.30 million and cash and short-term investments were $59.27 million. The company’s total short-term debt was $29,431,000 while long-term debt stood at $0.
Pear Therapeutics Inc’s total current assets stands at $72.96 million while long-term investments were $0 and short-term investments were $10.97 million. Its net receivables were $6.94 million compared to accounts payable of $3.26 million and inventory worth $69000.00.
In 2024, Pear Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $1.07 million.
Comparatively, Pear Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.01
- 52-Week High
- $3.33
- 52-Week Low
- $0.003
- Analyst Target Price
- $3.83
Pear Therapeutics Inc stock is currently trading at $0.01 per share. It touched a 52-week high of $3.33 and a 52-week low of $3.33. Analysts tracking the stock have a 12-month average target price of $3.83.
Its 50-day moving average was $0.02 and 200-day moving average was $1.14 The short ratio stood at 2.33 indicating a short percent outstanding of 0%.
Around 1652.7% of the company’s stock are held by insiders while 5954.5% are held by institutions.
Frequently Asked Questions About Pear Therapeutics Inc
Similar Industry Stocks (Biotechnology & Medical Research)
Most Active
Top Gainers
Top Losers
About
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines in the United States. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastroenterology, cardiology, and oncology. Pear Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. On April 7, 2023, Pear Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.